Centuple Global Ltd Upgraded to Sell as Valuation and Technicals Improve

Technical Trends Shift to Mildly Bearish

The primary catalyst for the upgrade stems from a shift in Centuple Global’s technical grade. Previously classified as bearish, the technical trend has now moderated to mildly bearish, indicating a less severe downtrend in price momentum. Weekly MACD readings have turned mildly bullish, suggesting some short-term positive momentum, although monthly MACD remains mildly bearish, reflecting longer-term caution.

Other technical indicators present a mixed picture: the Relative Strength Index (RSI) on both weekly and monthly charts shows no clear signal, while Bollinger Bands remain bearish on the weekly scale and mildly bearish monthly. Daily moving averages continue to signal bearishness, but the KST (Know Sure Thing) indicator has improved to mildly bullish weekly, offset by mildly bearish monthly readings. Dow Theory analysis reveals no definitive trend on either timeframe, and On-Balance Volume (OBV) data is inconclusive.

These nuanced technical signals collectively justify the upgrade from a Strong Sell to a Sell rating, reflecting a potential bottoming out of the stock’s price action, albeit with limited conviction for a sustained rally.

Valuation Grade Upgraded to Very Attractive

Centuple Global’s valuation grade has improved significantly, moving from attractive to very attractive. The company currently trades at a price-to-earnings (PE) ratio of 11.62, which is substantially lower than many of its pharmaceutical peers such as Ind-Swift Laboratories (PE 51.93) and Shukra Pharma (PE 80.39). This discount is further emphasised by an enterprise value to EBITDA ratio of 12.04 and a remarkably low PEG ratio of 0.01, indicating that the stock is undervalued relative to its earnings growth potential.

Return on Capital Employed (ROCE) stands at a robust 22.15%, while Return on Equity (ROE) is an impressive 72.63%, underscoring efficient capital utilisation and strong profitability for shareholders. The company’s EV to Capital Employed ratio is a modest 2.76, reinforcing the view that the stock is trading at a bargain compared to its capital base and earnings power.

This valuation improvement is a key factor in the rating upgrade, signalling that the market may be underestimating Centuple Global’s intrinsic value despite its recent price weakness.

Financial Trend Remains Challenging Despite Recent Positives

While the company has reported positive financial performance in Q1 FY26-27, including net sales of ₹279.41 crores over the last six months with a staggering growth rate of 2,236.20%, the overall financial trend remains weak. Centuple Global continues to incur operating losses and exhibits a weak long-term fundamental strength profile.

The company’s ability to service debt is poor, with an average EBIT to interest coverage ratio of just 0.45, indicating vulnerability to financial stress. Additionally, the average ROCE over time is a modest 8.26%, reflecting low profitability per unit of total capital employed. These factors contribute to a cautious outlook on the company’s financial health despite recent quarterly improvements.

Moreover, the stock has underperformed the broader market significantly, delivering a negative return of -36.01% over the past year compared to the Sensex’s -11.20%. Year-to-date losses are even more pronounced at -72.1%, far exceeding the Sensex’s -15.62% decline. This underperformance highlights the challenges the company faces in regaining investor confidence and market share.

Quality Assessment and Institutional Interest

Centuple Global’s quality grade remains low, reflecting its weak long-term fundamentals and operating losses. However, the company has demonstrated consistent positive quarterly results over the last six quarters, signalling some operational improvements. The stock’s 52-week price range is wide, with a high of ₹144.40 and a low of ₹28.42, currently trading near the lower end at ₹31.88, which may attract value-focused investors.

Institutional investors have increased their stake by 2.56% in the previous quarter, now holding 11.15% of the company’s shares. This growing institutional participation suggests that more sophisticated investors see potential value in Centuple Global, possibly anticipating a turnaround or undervaluation correction.

Comparative Performance and Market Context

Over longer time horizons, Centuple Global’s performance remains disappointing. While the Sensex has delivered returns of 9.24% over three years, 22.37% over five years, and an impressive 158.06% over ten years, Centuple Global’s returns for the same periods are unavailable or negative, underscoring its laggard status within the Pharmaceuticals & Biotechnology sector.

Shorter-term returns also paint a bleak picture, with the stock falling 0.38% in the past week and 8.13% over the last month, both underperforming the Sensex’s declines of 2.27% and 6.54%, respectively. This persistent underperformance highlights the challenges the company faces in regaining momentum despite recent technical and valuation improvements.

Conclusion: A Cautious Upgrade Reflecting Mixed Signals

The upgrade of Centuple Global Ltd’s investment rating from Strong Sell to Sell is primarily driven by a technical trend improvement from bearish to mildly bearish and a significant enhancement in valuation metrics, now classified as very attractive. Despite these positives, the company’s financial trend and quality fundamentals remain weak, with ongoing operating losses, poor debt servicing ability, and underwhelming long-term returns.

Investors should weigh the company’s attractive valuation and improving technical signals against its fundamental challenges and historical underperformance. The increased institutional interest may provide some support, but the stock remains a high-risk proposition within the micro-cap pharmaceutical space.

Overall, the rating upgrade signals a potential stabilisation in the stock’s outlook but stops short of endorsing a buy, reflecting a cautious stance amid mixed data points.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today